Dileep Reddy Rampa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dileep Reddy Rampa has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jangsoon Lee
University of Hawaii Comprehensive Cancer Center, University of Hawaii, Honolulu, Hawaii, USA
17 shared publications - Naoto T. Ueno
University of Hawaiʻi Cancer Center Inflammatory Breast Cancer Clinic and Research Program, Honolulu, USA
17 shared publications - Bharat S. Kuntal
Cancer Biology Program, University of Hawai’i Cancer Center, Honolulu, Hawai’i
8 shared publications - Chalothorn Wannaphut
University of Hawai'i at Manoa John A Burns School of Medicine
8 shared publications - Debu Tripathy
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
8 shared publications - Elizabeth S. Nakasone
University of Hawaii Cancer Center, University of Hawai'i at Mānoa, Honolulu, HI, USA
8 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 5 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 2 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Supplementary Table 3 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-8 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Including supplementary figures and legends, and supplementary references.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-8 from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Including supplementary figures and legends, and supplementary references.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose:Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches.Experimental Design:We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models.Results:Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo.Conclusions:Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose:Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches.Experimental Design:We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models.Results:Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo.Conclusions:Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- Top Cited Papers
- 27 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1454-1461
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose: Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches. Experimental Design: We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models. Results: Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo. Conclusions: Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- 27 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1454-1461
Top Cited PapersPayload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
Purpose: Antibody–drug conjugates (ADC) have transformed the treatment of breast cancer. FDA-approved ADC such as trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) have demonstrated clinical benefit; however, drug resistance will almost inevitably emerge in the metastatic setting, and there is no established strategy for selecting subsequent ADC after disease progression following the first exposure to the ADC. This study aimed to define mechanisms of acquired resistance and evaluate rational sequencing approaches. Experimental Design: We generated breast cancer cell lines resistant to T-DXd (TDXd-R) and SG (SG-R). We assessed antigen expression, internalization, and resistance pathways, including efflux transporter activity. To identify therapeutic strategies, we tested the efficacy of ADC carrying non–topoisomerase I (Topo1) payloads in in vitro and in vivo models. Results: Resistance in both TDXd-R and SG-R models was primarily mediated by payload-specific factors, notably upregulation of efflux transporters, rather than loss of antigen expression. Switching to ADC with mechanistically different payloads, including microtubule inhibitors, restored antitumor activity in vitro and in vivo. Conclusions: Cross-resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target. Our data also suggest that the clinical benefit of sequential Topo1-based ADC may be reduced following disease progression on a Topo1-based ADC, likely due to these shared resistance pathways. Importantly, switching to ADC with non–cross-resistant payload classes may offer a more effective approach to guide ADC sequencing in patients with metastatic breast cancer, supporting payload diversification as a clinically actionable strategy.
- Open Access
- 12 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8896
Dual Therapeutic Impact of AXL Inhibitor AB-329: Chemotherapy Sensitization and Immune Microenvironment Reprogramming in TNBC
AXL, a receptor tyrosine kinase, has emerged as a promising therapeutic target in triple-negative breast cancer (TNBC) due to its critical roles in tumor progression, metastasis, and immune evasion. In this study, we investigated the antitumor efficacy and immunomodulatory potential of AB-329, a selective AXL kinase inhibitor, in preclinical models of TNBC. Transcriptome analysis and single-cell RNA sequencing datasets revealed elevated AXL expression in mesenchymal TNBC subtypes and a negative association with immune cell infiltration. While AB-329 demonstrated moderate antiproliferative effects as a monotherapy, its combination with paclitaxel led to substantially enhanced antiproliferative and anti-metastatic effects compared to gemcitabine, DXd, and SN-38. In murine TNBC allograft models, the combination of AB-329 and paclitaxel significantly reduced tumor growth, and AB-329 increased activated natural killer (NK) cell infiltration in humanized mouse models. Analysis of human breast cancer tissue further confirmed that low AXL expression is associated with a higher presence of NK cells in the tumor. These findings suggest that AB-329 not only augments chemotherapy efficacy but also reshapes the tumor immune microenvironment, supporting its further development as a dual-action therapeutic strategy for AXL-positive TNBC.
- 12 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8896
Open AccessDual Therapeutic Impact of AXL Inhibitor AB-329: Chemotherapy Sensitization and Immune Microenvironment Reprogramming in TNBC
AXL, a receptor tyrosine kinase, has emerged as a promising therapeutic target in triple-negative breast cancer (TNBC) due to its critical roles in tumor progression, metastasis, and immune evasion. In this study, we investigated the antitumor efficacy and immunomodulatory potential of AB-329, a selective AXL kinase inhibitor, in preclinical models of TNBC. Transcriptome analysis and single-cell RNA sequencing datasets revealed elevated AXL expression in mesenchymal TNBC subtypes and a negative association with immune cell infiltration. While AB-329 demonstrated moderate antiproliferative effects as a monotherapy, its combination with paclitaxel led to substantially enhanced antiproliferative and anti-metastatic effects compared to gemcitabine, DXd, and SN-38. In murine TNBC allograft models, the combination of AB-329 and paclitaxel significantly reduced tumor growth, and AB-329 increased activated natural killer (NK) cell infiltration in humanized mouse models. Analysis of human breast cancer tissue further confirmed that low AXL expression is associated with a higher presence of NK cells in the tumor. These findings suggest that AB-329 not only augments chemotherapy efficacy but also reshapes the tumor immune microenvironment, supporting its further development as a dual-action therapeutic strategy for AXL-positive TNBC.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor–Positive Triple-Negative Breast Cancer by Inhibiting c-MYC–mediated Tumorigenesis
Supplementary Figure S4. Enzalutamide and KRLS-017 had no synergistic effect in AR-negative HCC1806 TNBC cells, and combination of enzalutamide and KRLS-017 reduced c-MYC transcription in AR+ LAR TNBC cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor–Positive Triple-Negative Breast Cancer by Inhibiting c-MYC–mediated Tumorigenesis
Supplementary Figure S4. Enzalutamide and KRLS-017 had no synergistic effect in AR-negative HCC1806 TNBC cells, and combination of enzalutamide and KRLS-017 reduced c-MYC transcription in AR+ LAR TNBC cells.